Jul 21, 2025
Neuraxpharm continues international expansion with launch of Neuraxpharm Australia
Jul 08, 2025
Neuraxpharm and Dizlin Pharmaceuticals Announce Global Strategic Co-Development Agreement Bringing Next-Generation Drug-Device Therapy to Patients with Advanced Parkinson's Disease
Jan 07, 2025
Neuraxpharm to further grow branded business with the acquisition of two leading narcolepsy treatments, Provigil® and Nuvigil®
Nov 14, 2024
Neuraxpharm reports another year of sustained growth and international expansion
Oct 01, 2024
Neuraxpharm expands operations into the Middle East
Feb 29, 2024
Rare Disease Day 2024 - Call for greater awareness of X-linked adrenoleukodystrophy and cerebral adrenoleukodystrophy - special film launched
Jan 28, 2021
Neuraxpharm selected for prestigious pilot program to supply medical cannabis in France
Jan 12, 2021
Neuraxpharm launches first product in Japan
Dec 14, 2020
Neuraxpharm establishes operations in the Republic of Ireland through the acquisition of Medinutrix
Apr 01, 2020
A Breakthrough in the Global Medical Cannabis Market: Neuraxpharm Enters the Medical Cannabis Market as the First-ever European Pharmaceutical Company to Market Medical Cannabis Products
Feb 25, 2020
Neuraxpharm Reinforces Presence in Poland
Jan 23, 2020
European CNS Specialist Neuraxpharm Strengthens Expansion into Austrian Market with Acquisition of easypharm
Nov 28, 2019
European CNS Specialist Neuraxpharm Expands Southern European Presence with Expansion into Portugal
Oct 29, 2019
European CNS Specialist Neuraxpharm Enters Booming CBD Market
Sep 24, 2019
Neuraxpharm Provides Business Update on a Transformational Year
Jul 31, 2019
European CNS Specialist Neuraxpharm Launches First Products in the United Kingdom
May 28, 2019
Neuraxpharm, the European CNS Specialist, Launches First Probiotic Product PS128(TM)
Mar 06, 2019
European CNS Specialist Neuraxpharm Appoints Dan Furrer as Head of Corporate Marketing